Drugmaker Data, Price Negotiation Timeline Tee Up Fight With HHS

The pharmaceutical industry is being cornered into negotiating lower prices than it may see fit, with little recourse under newly proposed guidance by the Biden administration, industry analysts and legal experts say.

Collecting data from pharmaceutical giants and measuring product benefits are among the sore spots for industry in newly released guidance from the Centers for Medicare & Medicaid Services. Stakeholders have until April 14 to weigh in on the 91-page guidance, which provides the clearest window to date into how the government is approaching its new authority over the prices of some of Medicare’s highest-cost drugs.

The CMS ...